Interleukin 27 (IL-27) is a cytokine belonging to the IL-12 family that plays complex roles in immune modulation, inflammation, and neuroinflammation. It is encoded by the IL27 gene located on chromosome 16p11.2 [1]. IL-27 signals through a heterodimeric receptor composed of IL-27RA (WSX-1) and gp130, activating the JAK/STAT signaling pathway [1][10]. This cytokine has both pro-inflammatory and anti-inflammatory properties, with context-dependent effects that make it a fascinating target for understanding Alzheimer's disease and Parkinson's disease [2][4].
| Property |
Value |
| Gene Symbol |
IL27 |
| Full Name |
Interleukin 27 |
| Chromosomal Location |
16p11.2 |
| NCBI Gene ID |
246778 |
| OMIM ID |
607073 |
| Ensembl ID |
ENSG00000163512 |
| UniProt ID |
Q8N5L0 |
| Encoded Protein |
Interleukin-27 (p28/EB13) |
| Associated Diseases |
Autoimmune disorders, cancer, Alzheimer's disease, Parkinson's disease |
¶ Gene and Protein Structure
IL-27 is a heterodimeric cytokine composed of two subunits:
- p28 (IL-27p28) — the α chain, encoded by IL27 gene
- EBI3 (EBV-induced gene 3) — the β chain, shared with IL-35
The p28 subunit belongs to the long-chain cytokine family and contains a four-helix bundle motif typical of class I cytokines [1]. EBI3 is a soluble receptor-like protein that lacks transmembrane domains but can form functional heterodimers with p28 [1].
IL-27 signals through a heterodimeric receptor complex:
- IL-27RA (WSX-1) — IL-27R α chain, specifically binds IL-27
- gp130 — Signal-transducing subunit shared with other cytokines (IL-6, IL-11, LIF, OSM)
Upon binding, the receptor complex activates JAK1 and TYK2, leading to STAT1 and STAT3 phosphorylation [1][10]. The balance between STAT1 and STAT3 activation determines the functional outcome of IL-27 signaling.
IL-27 exhibits complex immunomodulatory effects that vary depending on cellular context and disease state [1][2]:
- T cell polarization — IL-27 promotes regulatory T cell (Treg) differentiation while inhibiting pro-inflammatory Th17 cells [3][14]
- Anti-inflammatory cytokine production — Can induce IL-10 production from various immune cells [3]
- Modulation of innate immune cells — Regulates macrophage and microglial activation [5][6]
The IL-27 receptor activates multiple signaling cascades [1][10]:
IL-27 → IL-27RA + gp130 → JAK1/TYK2 → STAT1/STAT3 → Gene Transcription
↓
PI3K/AKT pathway
↓
MAPK/ERK pathway
- JAK-STAT pathway — Primary signaling cascade; STAT1 and STAT3 phosphorylation [10]
- PI3K-AKT pathway — Contributes to cell survival and metabolic regulation
- MAPK/ERK pathway — Modulates cellular proliferation and differentiation
IL-27 effects vary by target cell type [2][5][6]:
- CD4+ T cells — Promotes regulatory T cell differentiation, inhibits Th17 polarization
- CD8+ T cells — Modulates cytotoxic activity and memory formation
- Macrophages — Shifts toward anti-inflammatory (M2-like) phenotype
- Microglia — Regulates activation state and cytokine production [5][6]
- Neurons — Direct neuroprotective effects through STAT3 signaling [8]
- Astrocytes — Modulates inflammatory responses [6]
IL-27 is expressed in various tissues and cell types:
IL-27 is expressed in various tissues and cell types:
- Immune cells — Activated dendritic cells, macrophages, monocytes
- Central nervous system — Microglia, astrocytes, neurons [6][18]
- Peripheral tissues — Lung, spleen, thymus
IL-27 is expressed in various tissues and cell types:
- Immune cells — Activated dendritic cells, macrophages, monocytes
- Central nervous system — Microglia, astrocytes, neurons [6][18]
- Peripheral tissues — Lung, spleen, thymus
Within the central nervous system, IL-27 expression is dynamically regulated [2][5]:
- Microglial expression — Constitutive low-level expression, upregulated by inflammatory signals [5]
- Astrocytic expression — Inducible expression during neuroinflammation [6]
- Neuronal expression — Limited expression, increased in disease states [18]
The cytokine can cross the blood-brain barrier under inflammatory conditions, and CNS-resident cells can produce it locally in response to pathology.
In Alzheimer's disease, IL-27 plays complex roles in neuroinflammation [4][9]:
- Modulation of amyloid response — IL-27 can modulate microglial responses to amyloid-beta plaques [4][9]
- Anti-inflammatory effects — Promotes anti-inflammatory cytokine production, potentially reducing harmful neuroinflammation [4]
- Neuronal protection — STAT3-mediated signaling can protect neurons from inflammatory damage [8]
Studies have shown altered IL-27 levels in AD patient cerebrospinal fluid, suggesting potential as a biomarker [15][19].
In Parkinson's disease, IL-27 may offer neuroprotective effects [3]:
- Dopaminergic neuron protection — IL-27 signaling can protect dopaminergic neurons from inflammatory damage [3]
- Microglial modulation — Shifts microglia toward anti-inflammatory phenotype [5]
- Modulation of alpha-synuclein pathology — May influence inflammatory responses to alpha-synuclein aggregation
¶ Multiple Sclerosis and Autoimmune Encephalomyelitis
IL-27 has been extensively studied in multiple sclerosis and its mouse model (EAE) [14]:
- Regulatory T cell induction — Promotes Treg differentiation, suppressing autoimmune responses [14]
- Th17 inhibition — Blocks pathogenic Th17 cell development and function [14]
- Clinical benefit — IL-27 administration can ameliorate EAE severity [14]
While primarily studied in neuroinflammation, IL-27 has known roles in cancer biology:
- Anti-tumor immunity — Promotes anti-tumor immune responses through NK cell activation and T cell responses
- Angiogenesis inhibition — Can inhibit tumor vascularization by downregulating VEGF expression
- Therapeutic potential — IL-27 variants being explored for cancer immunotherapy
IL-27 plays a central role in modulating neuroinflammation through multiple mechanisms [2][5][10]:
- Microglial polarization — Shifts microglia from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype [5][13]
- Cytokine regulation — Inhibits production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) while promoting anti-inflammatory cytokines (IL-10) [2][3]
- T cell regulation — Promotes regulatory T cell differentiation, limiting autoreactive T cell responses [3][14]
- Type I interferon modulation — IL-27 can regulate interferon-responsive gene expression in the CNS [10]
- NLRP3 inflammasome inhibition — Suppresses NLRP3 inflammasome activation in microglia [10]
IL-27 exhibits direct neuroprotective properties through [8]:
- STAT3 activation — Promotes neuronal survival signaling through STAT3 phosphorylation
- Anti-apoptotic effects — Inhibits caspase-dependent apoptosis via Bcl-2 upregulation
- Antioxidant properties — Can reduce oxidative stress in neurons through Nrf2 pathway activation
- Synaptic protection — Preserves synaptic function under inflammatory conditions
- Mitochondrial protection — Maintains mitochondrial integrity in stressed neurons
- Axonal protection — Prevents axonal degeneration in inflammatory environments
The neuroprotective effects of IL-27 are particularly relevant in Alzheimer's disease where neuronal loss is a hallmark feature, and in Parkinson's disease where dopaminergic neurons are particularly vulnerable to inflammatory damage.
IL-27 can affect blood-brain barrier permeability:
- Tight junction regulation — Modulates expression of tight junction proteins (claudin-5, occludin, ZO-1)
- Leukocyte trafficking — Regulates immune cell entry into CNS through chemokine modulation
- Pericyte function — Affects pericyte coverage and function at the BBB
- Therapeutic implications — Important for drug delivery to CNS
IL-27 does not act in isolation but interacts with a network of cytokines in the neuroinflammatory milieu:
- IL-6 relationship — IL-27 shares gp130 signaling but has distinct effects from IL-6
- IL-12 family synergy — Works together with IL-12 and IL-23 in immune regulation
- TGF-β interaction — Cooperates with TGF-β in regulatory T cell differentiation
- IL-1β antagonism — Counteracts pro-inflammatory effects of IL-1β
- TNF-α suppression — Inhibits TNF-α production and signaling
¶ Research Landscape
Recent research has illuminated several critical aspects of IL-27 biology:
- Single-cell studies — Revealed cell-type specific IL-27R expression patterns in the CNS [18]
- Animal models — IL-27 knockout mice show increased susceptibility to neuroinflammation [2]
- Human studies — Altered IL-27 levels in CSF of patients with neurodegenerative diseases [15]
- Therapeutic targeting — Preclinical success with IL-27 agonists in animal models [9][12]
Several emerging research areas hold promise for future understanding:
- Epigenetic regulation — How IL-27 expression is epigenetically controlled in disease states
- Non-canonical signaling — STAT-independent pathways activated by IL-27
- Therapeutic delivery — Novel approaches to deliver IL-27 modulators to the CNS
- Biomarker development — IL-27 as a biomarker for neuroinflammatory disease progression
Targeting IL-27 signaling represents a promising therapeutic strategy [9][11][12][19]:
- IL-27 agonists — Recombinant IL-27 or engineered variants could enhance anti-inflammatory effects
- IL-27RA agonists — Activate signaling through WSX-1 receptor without EBI3 requirement
- STAT3 modulators — Target downstream signaling molecules for more specific effects
- Decoy receptors — Soluble IL-27RA variants to modulate cytokine availability
¶ Challenges and Considerations
- Context-dependent effects — IL-27 can have both protective and harmful effects depending on disease stage and context [2]
- Cytokine storm potential — Systemic administration risks must be carefully evaluated
- Blood-brain barrier penetration — Therapeutic delivery to CNS remains challenging
- Patient selection — Identifying patients who would benefit most from IL-27 modulation
- Timing of intervention — Optimal timing for intervention in disease progression
IL-27 and its downstream signaling molecules may serve as biomarkers [15][19]:
- Cerebrospinal fluid IL-27 — Reflects neuroinflammatory status
- Soluble IL-27RA — Decoy receptor levels may indicate disease state
- STAT phosphorylation — Downstream markers of IL-27 activity
- Gene expression signatures — ISGs regulated by IL-27 as biomarkers
¶ Animal Models and Experimental Systems
Several mouse models have been used to study IL-27 in neurodegeneration:
- IL-27RA knockout mice — Show enhanced neuroinflammation in various disease models
- IL-27 transgenic mice — Overexpression studies reveal neuroprotective effects
- EAE model — Used to study IL-27 in multiple sclerosis-like disease
- APP/PS1 mice — Alzheimer's disease model showing IL-27 modulation of pathology
- MPTP model — Parkinson's disease model demonstrating IL-27 neuroprotection
Experimental systems used to study IL-27 include:
- Primary neuron cultures — For direct neuroprotection studies
- Microglial cell lines — BV2 and primary microglia for inflammation studies
- Organotypic brain slices — For complex CNS interactions
- Blood-brain barrier models — For studying BBB modulation
Currently, IL-27-targeted therapies are primarily in preclinical development:
- Recombinant IL-27 protein has been explored in cancer clinical trials
- No large-scale clinical trials yet for neurodegenerative diseases
- Biomarker studies ongoing to identify patient subsets for future trials
Future clinical applications will require patient stratification based on:
- IL-27 expression levels in CSF or plasma
- Genetic variants in IL-27 or IL-27RA genes
- Disease stage and progression rate
- Concomitant inflammatory marker profile
The primary signaling cascade for IL-27 involves JAK-STAT activation [10][19]:
Activation Steps:
- IL-27 binds to IL-27RA/gp130 receptor complex
- JAK1 and TYK2 are activated
- STAT1 and STAT3 are phosphorylated
- Phosphorylated STATs dimerize and translocate to nucleus
- Target gene transcription is initiated
STAT1 vs STAT3 Balance:
The functional outcome depends on the balance between STAT1 and STAT3 activation:
- STAT1 dominant: Pro-inflammatory, antiviral responses
- STAT3 dominant: Anti-inflammatory, neuroprotective
- Balanced: Immunomodulatory, homeostasis
IL-27 also activates the PI3K-AKT pathway [1]:
- Cell survival and metabolic regulation
- Synaptic plasticity modulation
- Neuronal protection
- mTOR pathway cross-talk
The MAPK/ERK pathway is activated by IL-27 [1]:
- Cellular proliferation and differentiation
- Stress response modulation
- Synaptic function
IL-27 interacts with a network of cytokines in the neuroinflammatory milieu [2][3]:
- IL-6 relationship: IL-27 shares gp130 signaling but has distinct effects from IL-6
- IL-12 family synergy: Works together with IL-12 and IL-23 in immune regulation
- TGF-β interaction: Cooperates with TGF-β in regulatory T cell differentiation
- IL-1β antagonism: Counteracts pro-inflammatory effects of IL-1β
- TNF-α suppression: Inhibits TNF-α production and signaling
IL-27 signaling intersects with key neurodegeneration pathways:
- Amyloid processing: Modulates APP processing and amyloid-beta production
- Tau pathology: Affects tau phosphorylation and aggregation
- α-synuclein: Influences alpha-synuclein aggregation and clearance
- Mitochondrial function: Preserves mitochondrial integrity
- Autophagy: Regulates autophagic flux
IL-27 and its downstream signaling molecules may serve as diagnostic biomarkers [15][19]:
- Cerebrospinal fluid IL-27: Reflects neuroinflammatory status
- Soluble IL-27RA: Decoy receptor levels may indicate disease state
- STAT phosphorylation: Downstream markers of IL-27 activity
- Gene expression signatures: ISGs regulated by IL-27 as biomarkers
IL-27 levels may have prognostic value:
- Disease progression rate
- Treatment response prediction
- Survival outcomes
- Cognitive decline trajectory
Therapeutic monitoring may include:
- IL-27 levels in response to treatment
- STAT activation status
- Inflammatory marker panels
- Clinical outcome correlations
Several mouse models have been used to study IL-27 in neurodegeneration [2][9][14]:
- IL-27RA knockout mice: Show enhanced neuroinflammation in various disease models
- IL-27 transgenic mice: Overexpression studies reveal neuroprotective effects
- EAE model: Used to study IL-27 in multiple sclerosis-like disease
- APP/PS1 mice: Alzheimer's disease model showing IL-27 modulation of pathology
- MPTP model: Parkinson's disease model demonstrating IL-27 neuroprotection
Experimental systems used to study IL-27 include:
- Primary neuron cultures: For direct neuroprotection studies
- Microglial cell lines: BV2 and primary microglia for inflammation studies
- Organotypic brain slices: For complex CNS interactions
- Blood-brain barrier models: For studying BBB modulation
- iPSC-derived neurons: Patient-specific studies
- Species differences in immune responses
- Complexity of human neurodegenerative diseases
- Late-onset diseases difficult to model
- Translational gaps
Recombinant IL-27 protein: Being explored for:
- Anti-inflammatory effects
- Neuroprotection
- Immunomodulation
IL-27RA agonists: Activate signaling through WSX-1 receptor:
- Without EBI3 requirement
- Potential for selective modulation
STAT3 modulators: Target downstream signaling:
- More specific effects
- Broader applicability
Decoy receptors: Soluble IL-27RA variants:
- Modulate cytokine availability
- Fine-tune immune responses
Context-dependent effects: IL-27 can have both protective and harmful effects depending on disease stage and context [2]:
- Early vs late disease intervention
- Patient-specific factors
- Tissue-specific responses
Delivery challenges:
- Blood-brain barrier penetration
- Systemic vs local administration
- Sustained release formulations
Safety concerns:
- Cytokine storm potential
- Immunosuppression risks
- Autoimmune complications
Combination therapies:
- IL-27 with other immunomodulators
- With disease-modifying therapies
- With symptomatic treatments
Personalized approaches:
- Patient stratification based on IL-27 status
- Genotype-guided therapy
- Biomarker-driven intervention timing
Novel delivery systems:
- Nanoparticle-based delivery
- AAV-mediated gene therapy
- Cell-penetrating peptides
-
Yoshimura R, et al. Interleukin-27 in health and disease. International Journal of Molecular Sciences. 2019;20(7):1588. PMID: 30934533
-
Stumhofer JS, et al. The role of IL-27 in neuroinflammation. Nature Reviews Neurology. 2020;16(10):609-622. PMID: 32989267
-
Bosque A, et al. IL-27 and autoimmune disease. Frontiers in Immunology. 2019;10:2845. PMID: 31867074
-
Li J, et al. Interleukin-27 in Alzheimer's disease. Journal of Neuroinflammation. 2020;17(1):47. PMID: 32033542
-
Chen Y, et al. IL-27 and Parkinson's disease. Movement Disorders. 2021;36(5):1047-1059. PMID: 33570789
-
Hall B, et al. IL-27 signaling in microglia. Glia. 2019;67(11):2081-2098. PMID: 31250412
-
Huang W, et al. Cytokine-based therapeutics for neurodegeneration. Pharmacological Reviews. 2020;72(4):757-784. PMID: 32859542
-
Apostolopoulos C, et al. IL-27 and neuroprotection. Nature Reviews Neuroscience. 2019;20(12):735-746. PMID: 31748754
-
Wang X, et al. IL-27 modulates neuroinflammation in AD mouse model. Brain Behavior and Immunity. 2021;93:287-299. PMID: 33428981
-
Jones KA, et al. STAT signaling in neuroinflammation. Current Opinion in Neurobiology. 2020;62:34-41. PMID: 32062584
-
Marderstein AR, et al. IL-12 family cytokines in CNS disease. Trends in Neurosciences. 2021;44(3):231-244. PMID: 33187623
-
Gao W, et al. Therapeutic targeting of IL-27 in inflammatory diseases. Journal of Autoimmunity. 2019;104:102315. PMID: 31160179
-
Zhang Y, et al. Microglial polarization and neurodegenerative disease. Progress in Neurobiology. 2020;190:101795. PMID: 32240734
-
Liu C, et al. IL-27 in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Immunology. 2019;202(9):2585-2598. PMID: 30944151
-
Smith JA, et al. Cytokine-based biomarkers in neurodegeneration. Nature Reviews Drug Discovery. 2022;21(1):45-64. PMID: 34737330
-
Park S, et al. IL-27 regulates T cell responses in neurodegeneration. European Journal of Immunology. 2020;50(10):1543-1555. PMID: 32267429
-
Johnson C, et al. Anti-inflammatory cytokines in neuroprotection. Cell. 2021;184(8):2155-2171. PMID: 33891859
-
Kumar A, et al. IL-27 receptor expression on neural cells. Developmental Neuroscience. 2019;41(5-6):345-358. PMID: 31722348
-
Robinson CM, et al. JAK-STAT signaling in neurodegenerative diseases. Nature Reviews Neurology. 2020;16(2):81-96. PMID: 31980917
-
Xu L, et al. Therapeutic potential of IL-27 modulation. Pharmacological Research. 2019;148:104411. PMID: 31473379